UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells

The Journal of pharmacology and experimental therapeutics, 2011-04, Vol.337 (1), p.155-161

2011

Volltextzugriff (PDF)

Alteration of SHP-1/p-STAT3 Signaling: A Potential Target for Anticancer Therapy

International journal of molecular sciences, 2017-06, Vol.18 (6), p.1234

2017

Volltextzugriff (PDF)

Protein tyrosine phosphatase 1B dephosphorylates PITX1 and regulates p120RasGAP in hepatocellular carcinoma

Hepatology (Baltimore, Md.), 2016-05, Vol.63 (5), p.1528-1543

2016

Volltextzugriff (PDF)

STAT3 mediates regorafenib-induced apoptosis in hepatocellular carcinoma

Clinical cancer research, 2014-11, Vol.20 (22), p.5768-5776

2014

Volltextzugriff (PDF)

Palbociclib induces activation of AMPK and inhibits hepatocellular carcinoma in a CDK4/6‐independent manner

Molecular oncology, 2017-08, Vol.11 (8), p.1035-1049

2017

Volltextzugriff (PDF)

Canagliflozin inhibits growth of hepatocellular carcinoma via blocking glucose-influx-induced β-catenin activation

Cell death & disease, 2019-05, Vol.10 (6), p.420, Article 420

2019

Volltextzugriff (PDF)

Nilotinib Induces Autophagy in Hepatocellular Carcinoma through AMPK Activation

The Journal of biological chemistry, 2013-06, Vol.288 (25), p.18249-18259

2013

Volltextzugriff (PDF)

Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma

Journal of hepatology, 2011-11, Vol.55 (5), p.1041-1048

2011

Volltextzugriff (PDF)

Reprogramming the oncogenic response: SET protein as a potential therapeutic target in cancer

Expert opinion on therapeutic targets, 2017-07, Vol.21 (7), p.685-694

2017

Volltextzugriff (PDF)

Sorafenib Overcomes TRAIL Resistance of Hepatocellular Carcinoma Cells through the Inhibition of STAT3

Clinical cancer research, 2010-11, Vol.16 (21), p.5189-5199

2010

Volltextzugriff (PDF)

Sorafenib and its derivative SC-1 exhibit antifibrotic effects through signal transducer and activator of transcription 3 inhibition

Proceedings of the National Academy of Sciences - PNAS, 2015-06, Vol.112 (23), p.7243-7248

2015

Volltextzugriff (PDF)

CIP2A is a target of bortezomib in human triple negative breast cancer cells

Breast cancer research : BCR, 2012-04, Vol.14 (2), p.R68-R68, Article R68

2012

Volltextzugriff (PDF)

Dovitinib induces apoptosis and overcomes sorafenib resistance in hepatocellular carcinoma through SHP-1-mediated inhibition of STAT3

Molecular cancer therapeutics, 2012-02, Vol.11 (2), p.452-463

2012

Volltextzugriff (PDF)

Tamoxifen induces apoptosis through cancerous inhibitor of protein phosphatase 2A-dependent phospho-Akt inactivation in estrogen receptor-negative human breast cancer cells

Breast cancer research : BCR, 2014-09, Vol.16 (5), p.431-431, Article 431

2014

Volltextzugriff (PDF)

Discovery of novel src homology region 2 domain‐containing phosphatase 1 agonists from sorafenib for the treatment of hepatocellular carcinoma

Hepatology (Baltimore, Md.), 2014-01, Vol.59 (1), p.190-201

2014

Volltextzugriff (PDF)

Cancerous inhibitor of protein phosphatase 2A mediates bortezomib-induced autophagy in hepatocellular carcinoma independent of proteasome

PloS one, 2013-02, Vol.8 (2), p.e55705

2013

Volltextzugriff (PDF)

Serine/threonine protein phosphatase 5 is a potential therapeutic target in cholangiocarcinoma

Liver international, 2018-12, Vol.38 (12), p.2248-2259

2018

Volltextzugriff (PDF)

Treatment of Liver Cancer

Cold Spring Harbor perspectives in medicine, 2015-09, Vol.5 (9), p.a021535-a021535

2015

Volltextzugriff (PDF)

Sorafenib Enhances Radiation-Induced Apoptosis in Hepatocellular Carcinoma by Inhibiting STAT3

International journal of radiation oncology, biology, physics, 2013-07, Vol.86 (3), p.456-462

2013

Volltextzugriff (PDF)

A combination of sorafenib and SC-43 is a synergistic SHP-1 agonist duo to advance hepatocellular carcinoma therapy

Cancer letters, 2016-02, Vol.371 (2), p.205-213

2016

Volltextzugriff (PDF)

OSU-03012, a novel celecoxib derivative, induces reactive oxygen species-related autophagy in hepatocellular carcinoma

Cancer research (Chicago, Ill.), 2008-11, Vol.68 (22), p.9348-9357

2008

Volltextzugriff (PDF)

Antagonizing SET Augments the Effects of Radiation Therapy in Hepatocellular Carcinoma through Reactivation of PP2A-Mediated Akt Downregulation

The Journal of pharmacology and experimental therapeutics, 2018-09, Vol.366 (3), p.410-421

2018

Volltextzugriff (PDF)

Src-homology protein tyrosine phosphatase-1 agonist, SC-43, reduces liver fibrosis

Scientific reports, 2017-05, Vol.7 (1), p.1728-11, Article 1728

2017

Volltextzugriff (PDF)

Inhibition of protein phosphatase 5 suppresses non-small cell lung cancer through AMP-activated kinase activation

Lung cancer (Amsterdam, Netherlands), 2017-10, Vol.112, p.81-89

2017

Volltextzugriff (PDF)

Downregulation of signal transducer and activator of transcription 3 by sorafenib:A novel mechanism for hepatocellular carcinoma therapy

World journal of gastroenterology : WJG, 2014-11, Vol.20 (41), p.15269-15274

2014

Volltextzugriff (PDF)

1 – 25 von 165

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(152)
Mit Volltextzugriff
(161)

Publikationsform

Artikel
(164)
Dissertationen
(1)

Sprache

Erscheinungsjahr

n.n

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells

Alteration of SHP-1/p-STAT3 Signaling: A Potential Target for Anticancer Therapy

Protein tyrosine phosphatase 1B dephosphorylates PITX1 and regulates p120RasGAP in hepatocellular carcinoma

STAT3 mediates regorafenib-induced apoptosis in hepatocellular carcinoma

Palbociclib induces activation of AMPK and inhibits hepatocellular carcinoma in a CDK4/6‐independent manner

Canagliflozin inhibits growth of hepatocellular carcinoma via blocking glucose-influx-induced β-catenin activation

Nilotinib Induces Autophagy in Hepatocellular Carcinoma through AMPK Activation

Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma

Reprogramming the oncogenic response: SET protein as a potential therapeutic target in cancer

Sorafenib Overcomes TRAIL Resistance of Hepatocellular Carcinoma Cells through the Inhibition of STAT3

Sorafenib and its derivative SC-1 exhibit antifibrotic effects through signal transducer and activator of transcription 3 inhibition

CIP2A is a target of bortezomib in human triple negative breast cancer cells

Dovitinib induces apoptosis and overcomes sorafenib resistance in hepatocellular carcinoma through SHP-1-mediated inhibition of STAT3

Tamoxifen induces apoptosis through cancerous inhibitor of protein phosphatase 2A-dependent phospho-Akt inactivation in estrogen receptor-negative human breast cancer cells

Discovery of novel src homology region 2 domain‐containing phosphatase 1 agonists from sorafenib for the treatment of hepatocellular carcinoma

Cancerous inhibitor of protein phosphatase 2A mediates bortezomib-induced autophagy in hepatocellular carcinoma independent of proteasome

Serine/threonine protein phosphatase 5 is a potential therapeutic target in cholangiocarcinoma

Treatment of Liver Cancer

Sorafenib Enhances Radiation-Induced Apoptosis in Hepatocellular Carcinoma by Inhibiting STAT3

A combination of sorafenib and SC-43 is a synergistic SHP-1 agonist duo to advance hepatocellular carcinoma therapy

OSU-03012, a novel celecoxib derivative, induces reactive oxygen species-related autophagy in hepatocellular carcinoma

Antagonizing SET Augments the Effects of Radiation Therapy in Hepatocellular Carcinoma through Reactivation of PP2A-Mediated Akt Downregulation

Src-homology protein tyrosine phosphatase-1 agonist, SC-43, reduces liver fibrosis

Inhibition of protein phosphatase 5 suppresses non-small cell lung cancer through AMP-activated kinase activation

Downregulation of signal transducer and activator of transcription 3 by sorafenib:A novel mechanism for hepatocellular carcinoma therapy

Suchergebnisse filtern